Northstar Oncology by BillionToOne ads

Track treatment response with molecular precision. Northstar Response enables real-time treatment monitoring with tissue-free convenience. Adding epigenomic insight from more than 2,000 cancer-specific methylation sites enables unmatched monitoring precision across advanced cancers.

We find more with less. Northstar Select is an ultrasensitive therapy selection assay built to push the limits of detection. Proven in a head-to-head study to uncover low VAF variants missed by other liquid biopsies.

Northstar’s single-molecule NGS (smNGS) platform combines comprehensive profiling with methylation-based epigenomics and treatment monitoring from a single blood-draw. Simplify your program with proven molecular insights that move your trials forward.

Northstar Select outperforms other liquid CGP tests by finding more actionable alterations. Real-world data highlights our ultrasensitive detection so you don’t miss potential opportunities for treatment.

Northstar’s liquid biopsy platform detects over 50% more alterations and offers ultra-sensitive copy number calling to support and accelerate biopharma development.

Northstar Response is the only methylation-based liquid biopsy with single-molecule precision. With tissue-free treatment monitoring, conveniently reveal molecular progression and assess tumor burden with precision. Monitor what matters.